Significant challenges facing HIV practitioners

Journal of Infectious Diseases

Volumn 197, Issue SUPPL. 3, 2008, Pages

  Bartlett, John G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; EDITORIAL; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL PRACTICE; MIXED INFECTION; OPPORTUNISTIC INFECTION; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; REBOUND; SURVIVAL TIME; TREATMENT FAILURE; VIRUS RESISTANCE;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DECISION MAKING; HEALTH OCCUPATIONS; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE;

EID: 44149113315     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/533417     Document Type: Editorial

References (15)

1. Hirsch MS. Initiating therapy: when to start, what to use. J Infect Dis 2008; 197(Suppl 3): S252-60 (in this supplement).
2. Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis 2008; 197(Suppl 3):S261-71 (in this supplement).
3. + count-guided interruption of antiretroviral treatment. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med 2006; 355:2283-96.
4. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-9.
5. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008; 197(Suppl 3):S272-8 (in this supplement).
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
7. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-41.
8. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A: D Study. Arch Intern Med 2006; 166:1632-41.
9. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Multicenter AIDS Cohort Study. Lancet 2002; 360:1921-6.
10. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197(Suppl 3):S279-93 (in this supplement).
11. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41:123-31.
12. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-70.
13. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008; 197(Suppl 3): S294-306 (in this supplement).
14. d'Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in EuroSIDA cohort. Ann Neurol 2004; 55:320-8.
15. Lohse N, Hansen AB, Pederson G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.